Company intelligence / Profile preview

Autotelic Therapeutics

Ownership: Private
Development stage: Phase 2

Overview

Proprietary antisense oligonucleotide (ASO) and small molecule platforms with 5 assets in development (3 ASO anti-cancer drugs, 2 small molecule drugs), aiming to tackle "undruggable" cancer targets. Clinical results not yet published as of latest info.

Therapeutic areas: PulmonologyOncology
Modalities: Antisense oligonucleotideSmall molecule
Industry: Biotech

Drug pipeline

4 assets

OT-101

Phase 2

Indications: Brain cancer, Pancreatic cancer, COVID-19

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Autotelic Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autotelic Therapeutics.

Explore the full profile